Abstract 5667
Background
DS-8201a is a novel antibody-drug conjugate comprised of a humanized HER2 antibody attached by a cleavable peptide-based linker to a topoisomerase I inhibitor; characterized by a high drug-to-antibody ratio of about 8. In an ongoing phase 1 trial, DS-8201a showed high and durable responses across multiple tumors, with a confirmed objective response rate (ORR) of 61.4% in previously T-DM1-treated HER2-positive (IHC 3+ or IHC2+ and ISH+) breast cancer (BC) and 31.6% in HER2 low-expressing (IHC 2+/1+ and ISH–) BC (Oct 2017 cutoff; Modi et al, SABCS 2017). Nivolumab, an anti-PD-1 antibody, is FDA-approved for metastatic urothelial carcinoma (UC) after platinum failure. A xenograft model of HER2-expressing cancer showed significantly increased survival with the combination of DS-8201a with an anti-PD-1 antibody vs either treatment alone (Iwata et al, ASCO 2017).
Trial design
This phase 1b, multicenter, open-label study will assess the combination of DS-8201a with nivolumab in previously chemotherapy-treated HER2-expressing advanced BC or UC. Previous treatment with anti-PD-1/PD-L1 therapy is an exclusion criterion. A dose escalation (part 1) will identify the recommended dose for expansion (RDE), and dose expansion (part 2) will evaluate efficacy and safety/tolerability of the DS-8201a RDE combination with nivolumab (360 mg IV; q3wk). Part 1 is a 3 + 3+3 design with 3 dose cohorts of DS-8201a (3.2, 5.4, and 6.4 mg/kg q3wk); enrollment will start at 3.2 mg/kg. Following RDE determination, enrollment in part 2 will open (Table); estimated total enrollment is 99–117. ORR is the primary efficacy endpoint; secondary endpoints include overall survival, disease control rate, duration of response, progression-free survival, time to response based on central review, and safety/tolerability. The study is open for enrollment as of May 2018.Table: 370TiP
| Part 2 Cohorts | |||
|---|---|---|---|
| Cohort | Cancer Type | HER2 Status | Approximate Enrollment |
| 1 | BC | HER2-positive (IHC 3+ or ISH+) | 30 |
| 2 | BC | HER2 low-expressing (IHC 2+/1+ and ISH–) | 15 |
| 3 | UC | HER2 high-expressing (IHC 3+/2+) | 30 |
| 4 | UC | HER2 low-expressing (IHC 1+) | 15 |
Clinical trial identification
NCT03523572.
Legal entity responsible for the study
Daiichi Sankyo, Inc.
Funding
Daiichi Sankyo, Inc.
Editorial Acknowledgement
Medical writing and editorial support was provided by Stefan Kolata, PhD of AlphaBioCom, LLC (King of Prussia, PA).
Disclosure
S.A. Hurvitz: Grants: Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, PUMA, Merrimack, Medivation, Dignitana, OBI Pharma, Biomarin, Cacadian, Lilly, Novartis, OBI Pharma, Bayer. M.D. Galsky: Consultancy fees: Genetech, Merck, Novartis, Astellas, AstraZeneca, and BMS; Stock/stock options: Dual Therapeutics. J. Shahidi, G. Zhang, S. Raza: Full time employee: Daiichi Sankyo, Inc. A. Necchi: Personal fees: Roche, Janssen; Grants and personal fees: Merck, AstraZeneca.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract